In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins

Nurhazimah, Hasbi (2022) In silico Docking Analysis of Bromelain Compound with Cancer Cell-Surface Receptor Proteins. [Final Year Project Report] (Unpublished)

PDF (Please get the password from TECHNICAL & DIGITIZATION MANAGEMENT UNIT, ext: 082-583913/ 082-583914) NURHAZIMAH BINTI HASBI_ft.pdf Restricted to Registered users only Download (1MB)

Abstract

Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina Bromelain compound is a bioactive compound belonging to the cysteine protease family which can be isolated from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted. from the stem of Ananas comosus (pineapple). The compound is known for carrying phytomedicine properties for treating various diseases including cancer through induction of apoptosis. The present research focuses on the insilico docking analysis of bromelain compound with cancer cell surface-receptor protein to study the best binding mode and the specific binding sites of the interaction on different cancer cell surface receptor proteins which are HER2, VEGFR1, CD44, TNFR-1A and EGFR. The docking process which was carried out through Autodock Vina shows that the binding affinity of the receptor ligand complex of bromelain with HER2, VEGFR1, CD44, EGFR and TNFR-1A were -8.9, -8.9, -7.8, -7.7 and -7.1 respectively. The result shows promising binding affinity of the interacting receptor-ligand complex and further study on the efficacy of bromelain compound in cancer treatment research should be conducted.

Actions (For repository members only: login required)

View Item